e-learning
resources
European Respiratory Review
2015
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Long-term experience in the treatment of alpha 1-antitrypsin deficiency: 25 years of augmentation therapy
Teschler Helmut
Source:
Eur Respir Rev 2015; 24: 46-51
Journal Issue:
March
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Teschler Helmut. Long-term experience in the treatment of alpha 1-antitrypsin deficiency: 25 years of augmentation therapy. Eur Respir Rev 2015; 24: 46-51
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Panel discussion on Basic translational and clinical research – building a career in paediatric pulmonology- experiences from clinicians in lower middle income countries
Related content which might interest you:
Impact of alpha 1-antitrypsin deficiency and prior augmentation therapy on patients' survival after lung transplantation
Source: Eur Respir J, 50 (3) 1700962; 10.1183/13993003.00962-2017
Year: 2017
Homecare setting of longterm augmentation therapy in alpha1 antitrypsin defiency patients leads to clinical stabilization
Source: International Congress 2017 – New frontiers in home care management of chronic lung diseases
Year: 2017
Phase I safety investigation of an aerosolized, recombinant alpha 1-antitrypsin in subjects with alpha 1-antitrypsin deficiency
Source: Eur Respir J 2004; 24: Suppl. 48, 228s
Year: 2004
A case report of alpha 1-antitrypsin deficiency in a six-month infant
Source: Eur Respir J 2004; 24: Suppl. 48, 228s
Year: 2004
Long-term effect of alpha-1-antitrypsin augmentation therapy on the decline of FEV1 in deficient patients
Source: Virtual Congress 2021 – Treatments for airway diseases
Year: 2021
Effects of biweekly Alpha1 antitrypsin replacement therapy: a case series
Source: Virtual Congress 2020 – Clinical and basic pharmacology for COPD
Year: 2020
Alpha 1 - antitrypsin deficiency: diagnosis and treatment
Source: Virtual Congress 2021 – Alpha 1 - antitrypsin deficiency: diagnosis and treatment
Year: 2021
Diagnosing alpha 1-antitrypsin deficiency: how to improve the current algorithm
Source: Eur Respir Rev 2015; 24: 52-57
Year: 2015
Comparison of outcomes in augmentation naïve and augmented patients with alpha-1 antitrypsin deficiency related lung disease.
Source: International Congress 2019 – COPD clinical studies: bronchodilators, corticosteroids and more
Year: 2019
The withdrawal of replacement therapy and outcomes in alpha-1 antitrypsin deficiency lung transplant recipients
Source: Eur Respir J, 53 (5) 1900055; 10.1183/13993003.00055-2019
Year: 2019
COVID-19 infection in Severe Alpha 1-antitrypsin deficiency: looking for a rationale
Source: Virtual Congress 2021 – Burden and epidemiology of COVID-19
Year: 2021
Efficacy of augmentation therapy for emphysema associated with alpha1-antitrypsin deficiency: enough is enough
Source: Eur Respir J 2016; 47: 35-38
Year: 2016
Reduction in incidence of exacerbations in patients with alpha 1 antitrypsin deficiency (A1ATD) treated with concentrates of alpha 1 antitrypsin (A1AT): REXA study
Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD
Year: 2011
Survival in individuals with severe alpha 1-antitrypsin deficiency (PiZZ) in comparison to a general population with known smoking habits
Source: Eur Respir J, 50 (3) 1700198; 10.1183/13993003.00198-2017
Year: 2017
Effect of intravenous alpha-1-antitrypsin augmentation therapy on proteinase-3-generated AaVal541 in deficient patients
Source: Virtual Congress 2021 – Airway pharmacology: translational and basic science
Year: 2021
Targeted screening programmes in COPD: how to identify individuals with alpha 1-antitrypsin deficiency
Source: Eur Respir Rev 2015; 24: 40-45
Year: 2015
Effect of augmentation therapy on immune function of patients with severe Alpha1-antitrypsin deficiency
Source: Annual Congress 2012 - COPD treatments: efficacy and safety
Year: 2012
Aα360: A measure of disease and treatment efficacy in alpha-1-antitrypsin (A1AT) deficiency
Source: Annual Congress 2010 - COPD: phenotyping and monitoring
Year: 2010
Does smoking impair the quality of life of 34 year olds with alpha-1 antitrypsin deficiency?
Source: Annual Congress 2011 - Smoking-related disorders and smoking prevention
Year: 2011
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept